Inside Selling: Greg Bishop Unloaded 392 Shares of Control4 (CTRL); Recro Pharma (REPH)’s Sentiment Is 1.65

Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company has market cap of $170.62 million. The Company’s lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain. It currently has negative earnings. The firm also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain.

Insider sale totalling approx. $9,800 U.S. Dollars was published online in a public document submitted to the U.S. Security and Exchange Commission on February 27, 2018. According to which, Greg Bishop, the GC – Chief Compl. Officer – Sec of Control4 Corp also an insider of the firm had sold precisely 392 shares – ( at $25.0 for a share ). This is not his first insider trade, in the last month, he unloaded another 40,792 shares worth $1,020,529 USD. This is a major stocks unloading, and one that is unlikely to stay unseen, as it decreased his ownership of the company to 0.04% market capitalization, for a total of 11,412 shares.

The stock decreased 1.44% or $0.36 during the last trading session, reaching $24.64. About 965,013 shares traded or 67.32% up from the average. Control4 Corporation (NASDAQ:CTRL) has risen 139.51% since February 28, 2017 and is uptrending. It has outperformed by 122.81% the S&P500.

Investors sentiment increased to 1.88 in 2017 Q3. Its up 0.09, from 1.79 in 2017Q2. It improved, as 16 investors sold Control4 Corporation shares while 34 reduced holdings. 52 funds opened positions while 42 raised stakes. 19.12 million shares or 7.32% more from 17.81 million shares in 2017Q2 were reported. New York State Common Retirement Fund holds 0% or 27,000 shares in its portfolio. Art Advsr Ltd has invested 0.05% in Control4 Corporation (NASDAQ:CTRL). Invesco Ltd accumulated 330,425 shares. Moreover, Group Inc One Trading Ltd Partnership has 0.01% invested in Control4 Corporation (NASDAQ:CTRL) for 19,372 shares. Blackrock Inc stated it has 0% of its portfolio in Control4 Corporation (NASDAQ:CTRL). Manufacturers Life The owns 18,462 shares or 0% of their US portfolio. Legal General Grp Pcl owns 36,223 shares. Ameriprise Fincl Inc stated it has 0% in Control4 Corporation (NASDAQ:CTRL). Franklin Resources holds 10,583 shares. Jacobs Levy Equity Mngmt has 0.06% invested in Control4 Corporation (NASDAQ:CTRL) for 98,200 shares. Citigroup has 0% invested in Control4 Corporation (NASDAQ:CTRL). Kistler owns 141 shares. Jpmorgan Chase holds 0% or 1,674 shares in its portfolio. Bancshares Of America De has 589,150 shares. Nordea Inv Mngmt has 12,900 shares for 0% of their portfolio.

Control4 Corporation provides smart home and business solutions for the connected home or business in the United States, Canada, and internationally. The company has market cap of $636.54 million. It offers Control4 solution that functions as the operating system of the home, integrating audio, video, lighting, temperature, security, communications, and other devices in the home automation market. It has a 41.07 P/E ratio. The company??s Control4 product line comprises the Control4 home operating system and the associated application software, and software development kits .

Analysts await Control4 Corporation (NASDAQ:CTRL) to report earnings on May, 3. They expect $0.03 EPS, up 400.00% or $0.04 from last year’s $-0.01 per share. CTRL’s profit will be $775,004 for 205.33 P/E if the $0.03 EPS becomes a reality. After $0.30 actual EPS reported by Control4 Corporation for the previous quarter, Wall Street now forecasts -90.00% negative EPS growth.

Among 7 analysts covering Control4 (NASDAQ:CTRL), 4 have Buy rating, 0 Sell and 3 Hold. Therefore 57% are positive. Control4 has $36.0 highest and $7.50 lowest target. $24.60’s average target is -0.16% below currents $24.64 stock price. Control4 had 20 analyst reports since July 31, 2015 according to SRatingsIntel. The rating was maintained by Maxim Group with “Hold” on Friday, November 3. The firm earned “Outperform” rating on Friday, September 8 by Cowen & Co. The firm earned “In-Line” rating on Tuesday, February 14 by Imperial Capital. As per Friday, August 4, the company rating was maintained by Cowen & Co. As per Friday, August 12, the company rating was maintained by Imperial Capital. Imperial Capital maintained the shares of CTRL in report on Monday, November 7 with “In-Line” rating. Needham downgraded Control4 Corporation (NASDAQ:CTRL) on Friday, October 30 to “Hold” rating. As per Friday, February 9, the company rating was maintained by Needham. The stock has “Buy” rating by Needham on Wednesday, May 31. As per Tuesday, November 17, the company rating was maintained by Imperial Capital.

Since February 13, 2018, it had 0 insider buys, and 8 insider sales for $3.15 million activity. PLAEHN MARTIN sold $1.02M worth of Control4 Corporation (NASDAQ:CTRL) on Tuesday, February 13. Shares for $17,343 were sold by Judd Bryce. $55,713 worth of stock was sold by Bishop Greg on Thursday, February 15. On Tuesday, February 20 the insider Novakovich Mark sold $706,831. $389,238 worth of Control4 Corporation (NASDAQ:CTRL) shares were sold by Cashen Susan.

The stock increased 0.11% or $0.01 during the last trading session, reaching $8.92. About 347,971 shares traded or 160.30% up from the average. Recro Pharma, Inc. (REPH) has risen 26.61% since February 28, 2017 and is uptrending. It has outperformed by 9.91% the S&P500.

Analysts await Recro Pharma, Inc. (NASDAQ:REPH) to report earnings on March, 5. They expect $-0.85 EPS, down 4.94% or $0.04 from last year’s $-0.81 per share. After $-0.48 actual EPS reported by Recro Pharma, Inc. for the previous quarter, Wall Street now forecasts 77.08% negative EPS growth.

Broadfin Capital Llc holds 4.12% of its portfolio in Recro Pharma, Inc. for 3.10 million shares. Deerfield Management Co owns 1.90 million shares or 0.77% of their US portfolio. Moreover, Carl Domino Inc has 0.31% invested in the company for 28,000 shares. The New York-based Opus Point Partners Management Llc has invested 0.2% in the stock. Kingdon Capital Management L.L.C., a New York-based fund reported 259,948 shares.